Novel GLP-1 Agonist Could Lead To Long-Lasting Type 2 Diabetes Treatment

Could a novel GLP-1 agonist lead to longer-lasting treatment for type 2 diabetes?New GLP-1 receptor agonists are being developed to improve blood sugar control and potentially extend dosing intervals for people with type 2 diabetes. In this episode, we examine how these medications work and how diabetes treatment is assessed in Europe.In this episode, we cover:• What type 2 diabetes is (insulin resistance with progressive beta-cell dysfunction)• What GLP-1 receptor agonists do (enhance insulin secretion, reduce glucagon, slow gastric emptying)• How newer agents aim to prolong therapeutic effect• Evidence from clinical trials and current limitations• Effects on weight, cardiovascular risk, and HbA1c• Potential side effects and contraindications• When injectable therapies are considered• Situations where prescription requests may be declinedDoctors assess HbA1c levels, BMI, kidney function, cardiovascular history, current medications, and hypoglycaemia risk before recommending GLP-1 therapy. Not all patients are suitable candidates. Some require in-person examination, blood testing, or specialist referral before treatment decisions are made.This episode reflects how type 2 diabetes management is reviewed within structured medical assessment in European telemedicine at Mobi Doctor.Read the full medical guide here:https://www.mobidoctor.eu/blog/novel-glp-1-agonist-could-lead-to-long-lasting-type-2-diabetes-treatment